Mode
Text Size
Log in / Sign up
N/A N=20 Randomized Quadruple-blind Treatment

Remediation of Auditory Recognition in Schizophrenia With tDCS

Schizophrenia · Schizoaffective Disorder

Enrolled (actual)
20
Serious AEs
0.0%
Results posted
Jul 2021
Primary outcome: Primary: Auditory Tone Matching Task — -4.3; 4.8 %correct, different trials

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Active Transcranial direct current stimulation (tDCS) (Device); Sham Transcranial direct current stimulation (tDCS) (Device); Auditory Remediation (Behavioral); Control computer activities (Behavioral)
Age
Adult · 18+ yrs
Sex
All
Sponsor
New York State Psychiatric Institute
Primary completion
Jan 2020

Outcome Measures

OutcomeResultp-value
PRIMARY
Auditory Tone Matching Task
-4.3; 4.8
SECONDARY
Auditory Emotion Recognition (AER) Task
-3.0; 5.1
SECONDARY
ER-40
-5.0; -1.3
SECONDARY
The Awareness of Social Inference Test (TASIT)
10; 0
SECONDARY
Auditory Mismatch Negativity (MMN)
-1.47; -.98

Summary

The purpose of this study is to determine whether transcranial direct current stimulation (tDCS), when combined with different forms of computer based training, improves the ability to discriminate small differences between sounds in people diagnosed with schizophrenia or schizoaffective disorder.

Eligibility Criteria

Inclusion Criteria

  • Age 18-55
  • Primary diagnosis of Schizophrenia or schizoaffective disorder
  • English fluency
  • Willing/capable to provide informed consent
  • Auditory tone matching deficits
  • Receiving stable doses of antipsychotic medication(s) for at least 2 weeks
  • IQ>75

Exclusion Criteria

  • Serious neurological disorder or medical condition/ treatment known to affect the brain. Neurological Disorder that affects the central nervous system (CNS), such as epilepsy, neurodegenerative disorders, movement disorders and sensory disorders.
  • Current or past history (within the last 6 months) of substance abuse or dependence (excluding nicotine)
  • Pregnancy or breastfeeding
  • Taking anticholinergic medication (e.g. Cogentin, Thorazine, Clozaril, thioridazine)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02869334). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search